• 1
    Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, et al. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 1998; 25: 12829.
  • 2
    Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002; 110: 141927.
  • 3
    Valleala H, Laasonen L, Koivula MK, Mandelin J, Friman C, Risteli J, et al. Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. J Rheumatol 2003; 30: 46873.
  • 4
    Lodder MC, Van Pelt PA, Lems WF, Kostense PJ, Koks CH, Dijkmans BA. Effects of high dose intravenous pamidronate on disease activity and bone metabolism in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2003; 30: 20802.
  • 5
    Maksymowych WP. Bisphosphonates for arthritis: a confusing rationale. J Rheumatol 2003; 30: 4304.
  • 6
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 65361.
  • 7
    Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 2001; 28 Suppl 6: 410.
  • 8
    Goldring SR, Gravallese EM. Bisphosphonates: environmental protection for the joint? Arthritis Rheum 2004; 7: 20447.
  • 9
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 10
    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 2068.
  • 11
    Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003; 30: 13856.
  • 12
    Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum 2003; 48: 6471.
  • 13
    McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 181427.
  • 14
    Petcu EB, Schug SA, Smith H. Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain. J Pain Symptom Manage 2002; 24: 2814.
  • 15
    Cheer SM, Noble S. Zoledronic acid. Drugs 2001; 61: 799805.